Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Achilles Therapeutics, a biotech start-up based in Stevenage, England, has raised about $120 million in series B financing to begin testing its personalized T-cell therapies in humans this year. Achilles is developing a method to isolate a class of T cells called tumor infiltrating lymphocytes (TILs) from a person’s tumors and enlarge a subset of those TILs that target specific mutations shared by multiple tumors in the individual. The firm will test the procedure as a way to use a patient’s own cells to treat lung cancer and melanoma.
This article has been sent to the following recipient: